Management of Salivary Gland Malignancy: ASCO GuidelineJ.L. Geiger, Patrick K. Ha, Christine M. Glastonbury et al.|Journal of Clinical Oncology|2021Cited by 401
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trialAssuntina G. Sacco, Ezra E.W. Cohen, Ruifeng Chen et al.|The Lancet Oncology|2021Cited by 257
Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 StudyLisa Licitra, Robert I. Haddad, Makoto Tahara et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 32